# Diabetic Neuropathy and Erectile Dysfunction: Unveiling the Neural Pathways Behind a Vascular Symptom

**Authors:** Virginia Zamponi, Rossella Mazzilli, Stefano Balducci, Antongiulio Faggiano, Jonida Haxhi

PMC · DOI: 10.3390/jcm15041621 · 2026-02-20

## TL;DR

This paper explores how diabetic neuropathy contributes to erectile dysfunction, suggesting a shift in understanding from purely vascular causes to a neurovascular perspective.

## Contribution

The paper provides a comprehensive review linking diabetic neuropathy to erectile dysfunction through neurovascular mechanisms.

## Key findings

- Diabetic neuropathy significantly contributes to erectile dysfunction through impaired sensory conduction and reflex pathways.
- Molecular mechanisms like oxidative stress and reduced BDNF are key in linking diabetes to neurovascular dysfunction.
- Current therapies like PDE5 inhibitors show reduced effectiveness in patients with significant neuropathy.

## Abstract

Erectile dysfunction (ED) is one of the most prevalent and disabling complications of diabetes mellitus (DM), thought to arise from the interaction of metabolic, vascular, and neural injury. Recent evidence indicates that diabetic neuropathy, affecting both somatic and autonomic pathways, plays a central role in the development of ED and is strongly associated with increased disease burden. Early neurophysiological studies documented impaired penile sensory conduction and abnormalities of sacral reflex pathways in diabetic men with ED, while more recent investigations have confirmed the contribution of cardiovascular autonomic neuropathy and small-fibre loss. At the molecular level, oxidative stress, advanced glycation end-product signalling, impaired nitric oxide bioavailability, and reduced neurotrophic support, particularly involving brain-derived neurotrophic factor (BDNF), emerge as key mechanisms linking diabetes to neural and neurovascular dysfunction. Although phosphodiesterase type-5 inhibitors remain first-line therapy, reduced responsiveness in patients with significant neuropathy highlights the importance of recognising the role of neurogenic mechanisms. Overall, the available evidence supports the conceptualisation of diabetic ED as a neurovascular manifestation within the broader spectrum of diabetic neuropathy rather than as a purely vasculogenic disorder. This review integrates historical and contemporary literature addressing the epidemiology, neurophysiology, pathophysiology and therapeutic implications of ED in diabetes, with a specific focus on its neuropathic substrate. These findings support a paradigm shift toward an integrated neurovascular approach to diabetic ED, highlighting the importance of early neuropathy-oriented assessment and paving the way for future regenerative and neuroprotective therapeutic strategies.

## Linked entities

- **Proteins:** BDNF (brain derived neurotrophic factor)
- **Diseases:** diabetes mellitus (MONDO:0005015), diabetic neuropathy (MONDO:0006626), erectile dysfunction (MONDO:0005362)

## Full-text entities

- **Genes:** NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, PDE5A (phosphodiesterase 5A) [NCBI Gene 8654] {aka CGB-PDE, CN5A, PDE5}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, NOS1 (nitric oxide synthase 1) [NCBI Gene 4842] {aka IHPS1, N-NOS, NC-NOS, NOS, bNOS, nNOS}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** type 1 (MESH:D003922), sensory loss (MESH:C580162), dysfunction (MESH:D006331), DPN (MESH:D010523), sexual disorder (MESH:D012734), neuropathic (MESH:D009437), type 1 and type 2 DM (MESH:D003924), Ischaemic injury of the vasa nervorum (MESH:C535984), axonal degeneration (MESH:D009410), penile flaccidity (MESH:D010409), Chronic (MESH:D002908), distal neuropathy (MESH:D020423), Neuropathy (MESH:D009422), myelin damage (MESH:D020279), retrograde ejaculation (MESH:D061686), metabolic nerve injury (MESH:D000080902), demyelination (MESH:D003711), hypertension (MESH:D006973), diabetes-related complications (MESH:D048909), Microvascular (MESH:D017566), ischaemic (MESH:D018917), Diabetic ED (MESH:D007172), vascular damage (MESH:D057772), vascular disorder (MESH:D002561), weight (MESH:D015431), neurovascular complications (MESH:D013901), microvascular complications (OMIM:603933), tract symptoms (MESH:D059411), CAN (MESH:D002318), Diabetic Neuropathy (MESH:D003929), smoking (MESH:D015208), obesity (MESH:D009765), parasympathetic impairment (MESH:D001342), lower (MESH:D017116), ejaculatory disorders (MESH:D009358), nerve regeneration (MESH:C537568), deficit (MESH:D009461), endoneurial ischaemia (MESH:D007511), metabolic (MESH:D008659), mitochondrial dysfunction (MESH:D028361), small-fibre dysfunction (MESH:D000071075), injury to (MESH:D014947), macrovascular disease (MESH:D004194), inflammation (MESH:D007249), neuroinflammation (MESH:D000090862), vasculogenic disorder (MESH:D018783), endothelial dysfunction (MESH:D014652), polyneuropathy (MESH:D011115), autonomic and sensory neuropathy (MESH:D012678), sexual dysfunction (MESH:D012735), Diabetic (MESH:D003920), neurogenic dysfunction (MESH:D001750), sexual complaint (MESH:D050035), microvascular insufficiency (MESH:D000309), neuroregenerative failure (MESH:D051437)
- **Chemicals:** lipid (MESH:D008055), ROS (MESH:D017382), glucose (MESH:D005947), VED (-), alprostadil (MESH:D000527), sulfonylureas (MESH:D013453), Li (MESH:D008094), Metformin (MESH:D008687), AGEs (MESH:D017127), cyclic AMP (MESH:D000242), NO (MESH:D009569), prostaglandin (MESH:D011453), alpha-lipoic acid (MESH:D008063), polyol (MESH:C024617)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12941465/full.md

---
Source: https://tomesphere.com/paper/PMC12941465